☰

Kevin S. Gorski, Ph.D. - Publications

Affiliations: 
2001 Johns Hopkins University, Baltimore, MD 
Area:
Molecular Biology, Immunology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dummer R, Gyorki DE, Hyngstrom J, Berger A, Conry R, Demidov L, Sharma A, Treichel SA, Gorski K, Anderson A, Faries M, Ross MI. Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.063  0.305
2018 Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 174: 1031-1032. PMID 30096300 DOI: 10.1016/J.Cell.2018.07.035  0.387
2018 Tchao N, Gorski K, Yuraszeck T, Sohn S, Ishida K, Wong H, Park K. PS7:135 Amg 592 is an investigational il-2 mutein that induces highly selective expansion of regulatory t cells Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Abstract.178  0.442
2018 Gorski KS, Stern J, Hsu Y-, Anderson A, Boedigheimer M, Tchao N. THU0031 Phenotype of foxp3+ regulatory t-cells expanded by the il-2 mutein, amg 592 in healthy subjects in phase 1, first-in-human study Annals of the Rheumatic Diseases. 77: 243-243. DOI: 10.1136/Annrheumdis-2018-Eular.7212  0.423
2018 Gogas H, Samoylenko I, Schadendorf D, Gutzmer R, Grob J, Sacco J, Gorski K, Anderson A, Liu C, Malvehy J. Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study Annals of Oncology. 29: viii443. DOI: 10.1093/Annonc/Mdy289.002  0.407
2017 Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 170: 1109-1119.e10. PMID 28886381 DOI: 10.1016/J.Cell.2017.08.027  0.444
2017 Tchao N, Gorski KS, Yuraszeck T, Sohn SJ, Ishida K, Wong H, Park K. Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells Blood. 130: 696-696. DOI: 10.1182/Blood.V130.Suppl_1.696.696  0.407
2016 Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298410 DOI: 10.1200/Jco.2016.67.1529  0.355
2016 Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon JS, Fernandez E, Kirkwood JM, Gajewski T, Gause CK, Chen L, ... Gorski K, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. Journal of Clinical Oncology. 34: 9568-9568. DOI: 10.1200/Jco.2016.34.15_Suppl.9568  0.401
2016 Althammer S, Steele K, Rebelatto M, Tan TH, Wiestler T, Schmidt G, Higgs B, Li X, Shi L, Jin X, Antal J, Gupta A, Ranade K, Binning G, Bellmunt J, ... ... Gorski KS, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0191-4  0.31
2016 Gorski K, Butz E, Leon F, Lebrec H, Tsuji WH. 847 The Fully Human Anti-IL-15 Antibody AMG 714, in Development for Celiac and Refractory Celiac Disease, Does Not Reduce Circulating Numbers of Human Natural Killer Cells or Preclude Their In Vitro Activation and Function Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)30690-4  0.313
2014 Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM, Chou J, Kaufman H. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. Journal of Clinical Oncology. 32: 9029-9029. DOI: 10.1200/Jco.2014.32.15_Suppl.9029  0.379
2013 Lebrec H, Horner MJ, Gorski KS, Tsuji W, Xia D, Pan WJ, Means G, Pietz G, Li N, Retter M, Shaffer K, Patel N, Narayanan PK, Butz EA. Homeostasis of human NK cells is not IL-15 dependent. Journal of Immunology (Baltimore, Md. : 1950). 191: 5551-8. PMID 24184554 DOI: 10.4049/Jimmunol.1301000  0.39
2009 Wang T, Jiang Q, Chan C, Gorski KS, McCadden E, Kardian D, Pardoll D, Whartenby KA. Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR. Blood. 113: 2906-13. PMID 19164597 DOI: 10.1182/Blood-2008-08-176354  0.643
2009 Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, Reddy LG, Lutterman JL, Piri MM, Proksch J, McGurran SM, Egging EA, Cochran FR, Lipson KE, Tomai MA, Gullikson GW. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunology, Immunotherapy : Cii. 58: 575-87. PMID 18791716 DOI: 10.1007/S00262-008-0581-7  0.435
2009 Gorski K, Green C, Belouski SS, Rees W, Vincent M, Ferbas J. T.116. A Whole Blood Immunophenotyping Assay to Monitor Dendritic Cell and Monocyte Subsets in Healthy Volunteers and Patients with Multiple Sclerosis Clinical Immunology. 131. DOI: 10.1016/J.Clim.2009.03.249  0.411
2008 Gorski K, Ferbas J, Tsuji W. Su.80. A Whole Blood Assay for Evaluation of Natural Killer Cell Functional Activity Clinical Immunology. 127. DOI: 10.1016/J.Clim.2008.03.431  0.307
2007 Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7119-25. PMID 18056192 DOI: 10.1158/1078-0432.Ccr-07-1443  0.332
2006 Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. International Immunology. 18: 1115-26. PMID 16728430 DOI: 10.1093/Intimm/Dxl046  0.405
2005 Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. Journal of Immunology (Baltimore, Md. : 1950). 174: 1259-68. PMID 15661881 DOI: 10.4049/Jimmunol.174.3.1259  0.364
2003 Gorski KS, Shin T, Crafton E, Otsuji M, Rattis FM, Huang X, Kelleher E, Francisco L, Pardoll D, Tsuchiya H. A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer. Molecular Immunology. 40: 35-47. PMID 12909129 DOI: 10.1016/S0161-5890(03)00085-3  0.72
2003 Shin T, Kennedy G, Gorski K, Tsuchiya H, Koseki H, Azuma M, Yagita H, Chen L, Powell J, Pardoll D, Housseau F. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. The Journal of Experimental Medicine. 198: 31-8. PMID 12847135 DOI: 10.1084/Jem.20030242  0.684
2003 Cui Y, Kelleher E, Straley E, Fuchs E, Gorski K, Levitsky H, Borrello I, Civin CI, Schoenberger SP, Cheng L, Pardoll DM, Whartenby KA. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nature Medicine. 9: 952-8. PMID 12778137 DOI: 10.1038/Nm882  0.72
2002 Whartenby KA, Straley EE, Kim H, Racke F, Tanavde V, Gorski KS, Cheng L, Pardoll DM, Civin CI. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood. 100: 3147-54. PMID 12384412 DOI: 10.1182/Blood-2002-01-0118  0.585
2002 Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, Tamada K, Mittler RS, Tsuchiya H, Pardoll DM, Chen L. Cutting edge: Expression of functional CD137 receptor by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 168: 4262-7. PMID 11970964 DOI: 10.4049/Jimmunol.168.9.4262  0.678
2001 Golgher D, Korangy F, Gao B, Gorski K, Jaffee E, Edidin M, Pardoll DM, Elliott T. An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin Journal of Immunology. 167: 147-155. PMID 11418643 DOI: 10.4049/Jimmunol.167.1.147  0.537
2001 Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM, Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. The Journal of Experimental Medicine. 193: 839-46. PMID 11283156 DOI: 10.1084/Jem.193.7.839  0.65
Show low-probability matches.